265
Views
13
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors

, , , , , , , , , , & show all
Pages 477-482 | Received 11 Jun 2015, Accepted 02 Jul 2015, Published online: 13 Oct 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Li Li, Nan-Nan Chen, Qi-Dong You & Xiao-Li Xu. (2021) An updated patent review of anticancer Hsp90 inhibitors (2013-present). Expert Opinion on Therapeutic Patents 31:1, pages 67-80.
Read now

Articles from other publishers (12)

Thomas L. Prince, Benjamin J. Lang, Yuka Okusha, Takanori Eguchi & Stuart K. Calderwood. 2023. The Networking of Chaperones by Co-Chaperones. The Networking of Chaperones by Co-Chaperones 141 158 .
Zi-Nan Li & Ying Luo. (2022) HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review). Oncology Reports 49:1.
Crossref
Maosen Huang, Linyao Cheng, SiSi Mo, Haiming Ru, Xianwei Mo & Linhai Yan. (2022) Evaluation of colorectal cancer liver metastases based on liquid biopsy combined with folate receptor– Positive circulating tumor cells and HSP90. Frontiers in Oncology 12.
Crossref
Kalliopi Ziaka & Jacqueline van der Spuy. (2022) The Role of Hsp90 in Retinal Proteostasis and Disease. Biomolecules 12:7, pages 978.
Crossref
Shuxian Yang, Haiyan Xiao & Li Cao. (2021) Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment. Biomedicine & Pharmacotherapy 142, pages 112074.
Crossref
Marilia Barreca, Virginia Spanò, Maria Valeria Raimondi, Chiara Tarantelli, Filippo Spriano, Francesco Bertoni, Paola Barraja & Alessandra Montalbano. (2021) Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. European Journal of Medicinal Chemistry Reports 1, pages 100004.
Crossref
Brittany Epp-Ducharme, Michael Dunne, Linyu Fan, James C. Evans, Lubabah Ahmed, Pauric Bannigan & Christine Allen. (2021) Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro. Scientific Reports 11:1.
Crossref
Maxim Shevtsov, Gabriele Multhoff, Elena Mikhaylova, Atsushi Shibata, Irina Guzhova & Boris Margulis. (2019) Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors. International Journal of Molecular Sciences 20:21, pages 5284.
Crossref
Sangkyu Park, Jeong-A Park, Jae-Hyung Jeon & Younghee Lee. (2019) Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage. Biomolecules & Therapeutics 27:5, pages 423-434.
Crossref
David M. Vail, Douglas H. Thamm & Julias M. Liptak. 2019. Withrow and MacEwen's Small Animal Clinical Oncology. Withrow and MacEwen's Small Animal Clinical Oncology 251 285 .
Reyhaneh Moradi-Marjaneh, Seyed Mahdi Hassanian, Gordon A. Ferns, Amir Avan & Majid Khazaei. 2019. Heat Shock Protein 90 in Human Diseases and Disorders. Heat Shock Protein 90 in Human Diseases and Disorders 47 84 .
Anita Sveen, Jarle Bruun, Peter W. Eide, Ina A. Eilertsen, Lorena Ramirez, Astrid Murumägi, Mariliina Arjama, Stine A. Danielsen, Kushtrim Kryeziu, Elena Elez, Josep Tabernero, Justin Guinney, Hector G. Palmer, Arild Nesbakken, Olli Kallioniemi, Rodrigo Dienstmann & Ragnhild A. Lothe. (2018) Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research 24:4, pages 794-806.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.